Seattle – (work wire) – NanoString Technologies, Inc. (NASDAQ:NSTG), the leading provider of life sciences tools for discovery and translated research, is reporting a shift in commercial leadership. Chad Brown, who has served as Senior Vice President of Sales and Marketing since June 2017, will move to the position of Part-Time Senior Counsel effective April 1, before retiring fully in March 2023. John D. has been appointed. of the Chief Commercial Officer effective immediately.
Mr. Brown joined NanoString in July 2017 and launched a comprehensive portfolio review, implementing fundamental improvements to sales operations, the global expansion of the business and the successful launch of the GeoMx digital geo-profile.
“I joined NanoString over four years ago to build a world-class business organization. I have enjoyed the journey and am proud to say we have achieved this goal, as evidenced by our strong fourth quarter results,” said Chad Brown. “I look forward to supporting the transition and will be rooting for John.” and the team as they continue to develop the biospatial marketplace.”
“I would like to extend my sincere thanks to Chad for being my trading partner for over four wonderful years. Chad led the restructuring of our sales approach, the expansion of our commercial team, and the launch of GeoMx DSP, culminating in achieving record 2021 revenues,” stated Brad Gray, President and CEO For NanoString Corporation. “John Gerace has spent the past several decades working in some of the most dynamic and competitive markets in the life sciences, developing a deep understanding of our customers and winning strategies. His experience in building leading brands across a wide range of life science tools and molecular diagnostics will help us bring our products into an increasingly global marketplace. Additionally, John’s experience in business development can help us strengthen our portfolio and ecosystem through partnerships and deal making.”
Mr. Gerace is a veteran Life Sciences CEO with 35 years of diversified industry experience. Over the past four years, Mr. Gerace has served as President of DiaSorin Molecular, LLC, DiaSorin SpA’s global molecular diagnostics business unit. Prior to DiaSorin, he was the president and co-founder of Calabri Biosciences LLC, a consulting firm that manages a portfolio of assets related to mobile healthcare diagnostics and monitoring. From April 2015 to December 2016, he was President and CEO of Freedom Meditech, an early commercial-stage medical device company, which he restructured and sold to Trividia Health, a subsidiary of SinoCare, Inc. A variety of roles within Applied Biosystems/Life Technologies, including as Vice President and General Manager of the PCR Systems business unit, and then as Head of the Applied Markets business unit, serving the forensic science, animal health and food safety market segments. Prior to Life Technologies, Mr. Gerace spent 14 years at Beckman Coulter in various leadership roles in sales, marketing and business development. John holds a BA in Chemistry and Biological Sciences with honors from UC Irvine and an MBA from Pepperdine University. He currently serves on the Board of Directors of the Iacocca Family Foundation, the UC Irvine Foundation, and University Lab Partners.
“Spatial biology has emerged as a critical force behind the next decade of life science research and future molecular diagnostics. NanoString is the clear leader in the spatial revolution, providing a complete ecosystem of spatial platforms including tools, assays, and bioinformatics tools spanning from discovery and translational research today, With the potential to power the next generation of clinical applications,” Mr. Geras said. “NanoString has an experienced executive team, a long history of technical innovation, and an enviable portfolio of technologies. I look forward to working with Brad and the team to grow the business and create shareholder value.”
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life sciences tools for localized discovery and search. The company provides three platforms that allow researchers to map the world of the living. Cited in more than 5,200 peer-reviewed publications, the nCounter® analysis system provides a method for characterizing the expression of hundreds of genes, proteins, miRNAs or copy number transcripts, simultaneously with high sensitivity and accuracy. NanoString’s GeoMx® digital spatial identification software enables highly multiplexed spatial profiling of RNA and protein targets in various types of samples, including FFPE tissue sections, and has been cited in over 90 peer-reviewed publications. CosMx spatial molecular imaging, with commercial availability expected in 2022, enables high-resolution, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations regarding demand for and growth in our products. Our business, future revenue growth, the impact of new products and expansion into new markets, the growth trajectory of our nCounter and GeoMx franchises, and the expected launch of new products and technologies. These statements are based on current assumptions, which involve risks and uncertainties that could cause actual results and outcomes to differ materially. These include risks and uncertainties, many of which are beyond our control, market acceptance of our products; delay or denial of regulatory approvals or permits for products or applications; The extent and duration of the impact of the COVID-19 pandemic and adverse conditions on the general domestic and global economic markets; the effects of the ongoing litigation; competition effect. The impact of extended sales, marketing, product development, and clinical activities on operating expenses; delays or other unexpected problems in connection with manufacturing and product development; In addition to other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this contract. NanoString Technologies disclaims any obligation to update these forward-looking statements.
NanoString, NanoString Technologies, the NanoString logo, GeoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.